Breast Cancer

Genomic Screening Can ID Undetected <i>BRCA1/2</i> Cancer Risk

Genomic Screening Can ID Undetected BRCA1/2 Cancer Risk

82 percent of variant carriers identified in exome sequencing had not undergone prior testing.

Second Opinion at NCI Center Valuable for Breast CA Patients

Second Opinion at NCI Center Valuable for Breast CA Patients

Almost 43% of those presenting to NCI center for second opinion have change in diagnosis.

Talazoparib Shows Antitumor Activity in Advanced Breast Cancer, Germline <i>BRCA</i> Mutation

Talazoparib Shows Antitumor Activity in Advanced Breast Cancer, Germline BRCA Mutation

By

Talazoparib, a poly(adenosine diphosphate-ribose) inhibitor, may significantly enhance progression-free survival in patients with advanced breast cancer and a germline BRCA1/2 mutation.

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.

Tucatinib May Be A Safe, Novel Treatment for <i>ERBB2/HER2</i>-Positive Breast Cancer

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

NAMS: Breast Cancer Diagnosis May Indicate Lower Vitamin D Levels, Obesity in Postmenopausal Women

NAMS: Breast Cancer Diagnosis May Indicate Lower Vitamin D Levels, Obesity in Postmenopausal Women

By

The North American Menopause Society has found that postmenopausal women with a breast cancer diagnosis may have vitamin D deficiency as well as higher rates of obesity.

Beyond <I>BRCA</i>: New Predisposition Genes Linked to Breast, Ovarian Cancers

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

By

Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.

Adjuvant Chemo With Endocrine Therapy for HR+/HER2- Breast Cancer

Adjuvant Chemo With Endocrine Therapy for HR+/HER2- Breast Cancer

By

Although endocrine therapy following surgery is recommended for HR-positive/HER2-negative, axillary node-negative breast cancers, the value of adjuvant chemotherapy in the setting of moderate risk is unclear.

Lumpectomy &#43; Radiation May Cut Breast Cancer Mortality in DCIS

Lumpectomy + Radiation May Cut Breast Cancer Mortality in DCIS

Lumpectomy, radiotherapy tied to reduction in breast cancer mortality vs lumpectomy, mastectomy.

<i>TGFB1</i> Mutation Ups Radiation-Induced Breast Fibrosis Risk

TGFB1 Mutation Ups Radiation-Induced Breast Fibrosis Risk

C-509T allele and postoperative cosmetic surgery significantly linked to breast fibrosis risk.

Higher Risk of In Situ Breast CA, Ovarian Tumors With Fertility Treatment

Higher Risk of In Situ Breast CA, Ovarian Tumors With Fertility Treatment

No increased risk of corpus uteri, invasive breast cancer for women undergoing assisted reproduction.

FDA Grants First Approval for CA Drug Under New Pilot Programs

FDA Grants First Approval for CA Drug Under New Pilot Programs

Ribociclib approved in combo with AI as endocrine tx for HR-positive, HER2-negative advanced breast CA.

Ribociclib Prolongs Progression-Free Survival in Premenopausal Breast Cancer

Ribociclib Prolongs Progression-Free Survival in Premenopausal Breast Cancer

By

Investigators report results from the MONALEESA-7 trial, which assessed ribociclib plus endocrine therapy in premenopausal women with advanced breast cancer.

Many Breast Cancer Survivors Do Not Undergo Annual Surveillance

Many Breast Cancer Survivors Do Not Undergo Annual Surveillance

In year 1, 13% did not undergo MRI or mammography; up to 19% by year 5.

Computer analysis is not better than human clinical evaluation when it comes to measuring breast density

Similar associations were observed with clinical BI-RADS and automated BI-RADS with respect to interval and screen-detected cancer.

Multi-analyte blood test detects 8 common cancers

Multi-analyte blood test detects 8 common cancers

A multi-analyte blood test, CancerSEEK, can detect 8 common cancer types, with high sensitivity and specificity.

<i>BRCA</i> might not affect young-onset breast cancer survival rates

BRCA might not affect young-onset breast cancer survival rates

Both patients with and without BRCA mutations have comparable survival rates.

Cancer risk in women who work night shifts long-term

Cancer risk in women who work night shifts long-term

For women who work night shifts, breast cancer risks increase by 3.3% for every 5 years of work.

Hormonal contraception use linked to an increased risk of breast cancer

Hormonal contraception use linked to an increased risk of breast cancer

By

Breast cancer diagnosis is higher among women who currently use or recently used contemporary hormonal contraceptives than among women who have never used hormonal contraceptives.

Breast cancer screening: a review of current mammography guidelines

Breast cancer screening: a review of current mammography guidelines

Consensus regarding mammography screening varies, and conflicting guidelines from medical organizations can cause confusion for patients and providers.

Non-hormone options available for estrogen depletion after breast cancer

Non-hormone options available for estrogen depletion after breast cancer

A variety of non-hormone options and therapies are available for treatment of estrogen-depletion symptoms and clinical problems after a diagnosis of breast cancer.

Annual mammography from age 40 decreases breast cancer mortality

Annual mammography from age 40 decreases breast cancer mortality

Thousands of US lives would be saved each year if women received annual mammograms starting at age 40.

Breast, ovarian cancer risks estimated for <i>BRCA1/BRCA2</i> mutation carriers

Breast, ovarian cancer risks estimated for BRCA1/BRCA2 mutation carriers

By

Breast cancer risk is increased with a larger number of first- and second-degree relatives diagnosed as having breast cancer for both BRCA1/BRCA2 carriers.

Mammogram referral, screening rates boosted with point-of-care screening program

Mammogram referral, screening rates boosted with point-of-care screening program

By

A breast cancer screening program helped improve mammography referral and screening rates in a federally qualified health center.

One alcoholic drink per day may increase breast cancer risk

One alcoholic drink per day may increase breast cancer risk

By

Drinking the equivalent of a small glass of wine or beer a day increases pre-menopausal breast cancer risk by 5% and post-menopausal breast cancer risk by 9%.

Low-dose aspirin reduces breast cancer risk

Low-dose aspirin reduces breast cancer risk

Developing breast cancer was associated inversely with taking 3 or more tablets of low-dose aspirin per week.

Integrative therapies during and after breast cancer treatment: a clinical practice guideline

Integrative therapies during and after breast cancer treatment: a clinical practice guideline

By

Evidence supports the routine use of mind-body practices, such as yoga, meditation, relaxation techniques, and passive music therapy, to address common mental health concerns in patients with breast cancer.

Acupressure effective for fatigue linked to breast cancer

Acupressure effective for fatigue linked to breast cancer

By

Nearly 70% of participants who self-administered acupressure therapy experienced improved levels of fatigue.

Long-term breast cancer care transitioning to primary care clinicians

Long-term breast cancer care transitioning to primary care clinicians

By

As breast cancer survivorship increases, NPs have taken on long-term patient care.

Additional adjuvant aromatase inhibitor therapy improves breast cancer outcomes

Additional adjuvant aromatase inhibitor therapy improves breast cancer outcomes

By

Extending adjuvant aromatase inhibitor treatment can decrease disease recurrence and increase survival in breast cancer patients.

Sign Up for Free e-newsletters